Banks struggles to justify LG CNS’ IPO valuation There is gap between IT service company’s OTC market value and P/E multiple valuation
Translated by Ryu Ho-joung 공개 2022-05-09 07:58:19
이 기사는 2022년 05월 09일 07:56 thebell 에 표출된 기사입니다.
Investment bankers are struggling to justify a higher valuation for LG CNS than its listed peer Samsung SDS in its planned initial public offering despite its strong earnings growth, as the South Korean information technology services company lacks strengths that differentiate it from its competitors.Investment banks invited by LG CNS to pitch for roles in its IPO put a valuation of between 6 trillion won and 7 trillion won ($5.5 billion) on the company based on what its stock is traded at in the over-the-counter market.
This valuation is higher than Samsung SDS, LG CNS’ closest peer listed on Kospi. Based on Tuesday’s closing price and 633.4 billion won in net profit in 2021, Samsung SDS’ price-to-earnings (P/E) ratio is around 17.7 times. This P/E ratio represents a valuation of only 4 trillion won for LG CNS based on its 2021 net profit.
LG CNS might be able to justify a higher valuation if it has strengths that can differentiate the company from its rivals. One of those strengths was its lower reliance on intercompany transactions.
Intercompany transactions accounted for 59% of LG CNS’ total consolidated revenue in 2019. But the proportion rose to 64% in 2021, closer to 68% for Samsung SDS. The figure could have further increased if revenue from LX Group, which spun off from LG Group in May last year, was included.
LG CNS is also making little progress with its new businesses. In 2019, the company created a data and analytics team as part of efforts to ramp up its cloud computing business. Kim Eun-saeng, former vice president of Dell Technologies, was named to lead the team. But without notable results, Kim stepped down from the role earlier this year.
“It will be difficult for LG CNS to justify the 7 trillion won valuation,” an investment banking source said. “There are not many things that can be done until the IPO except hoping market conditions improve.” (Reporting by Yoon-shin Choi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- '벼랑 끝 격돌' 대유위니아 vs 홍원식, 전부 걸었다
- [ICTK road to IPO]경쟁자 없는 '차세대 보안칩', 2000억 후반 밸류 '정조준'
- CG인바이츠, 화일약품 지원 축소 11년 동행 '선긋기'
- [K-바이오 클러스터 기행|대전]대전 바이오 구심점, 20년 역사 바이오헬스케어협회
- 코인원, 이용규 CPO 영입…신규 서비스 출시 속도
- [코스닥 코스메틱 리뉴얼]마스크팩 잘나가던 지피클럽, 색조화장 '코디 인수'
- [K-배터리 밸류업 리포트]'오너 경영체제' 원준, 승계작업 '언제쯤'
- [thebell note]제약바이오는 다이어트 중
- [바이오텍 유증·메자닌 승부수]브릿지바이오, 유무상증자에 '대표 지분 블록딜' 왜?
- [제일약품의 온코닉테라퓨틱스 첫 '신약']성장성·사업성 갖춘 IPO 기대주 '밸류업' 이유 더 있다